ClinicalTrials.gg
Active, not recruitingNCT02747485DIFFUsEUpdated May 19, 2026

Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study)

An interventional study of Cardiac MRI and blood samples in Valve Heart Diseases, sponsored by Assistance Publique Hopitaux De Marseille. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
316
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.

Planned enrollment
12th of 31
316 · median 228
Started
2016
with 2 others
No phase
27 of 48
5 open now
Primary completion
2026-11
later than 8 of 21 live
Registered
15th of 48
by date
Lead sponsor
1 of 48
Assistance Publique Hopitaux De Marseille

Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 12th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2016, is one of 27 with no phase, reaches primary completion later than 8 of the 21 other live ones, and was the 15th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Valve Diseases with a site in France, or all of them as a file.
02

Study summary

New strategies are needed to early detect myocardial involvement in these diseases. Histological studies showed that diffuse fibrosis and cardiomyocyte hypertrophy precede the LV remodelling (dilatation) observed by cardiac imaging. Quantification of LV diffuse myocardial fibrosis using magnetic resonance imaging (MRI) could reach this goal. Recently, contrast enhanced cardiac MRI has been used to measure the extracellular volume fraction (ECV) of the myocardium, and it has been able to detect diffuse myocardial fibrosis. In diseases in which increased collagen deposition enlarges the extra-cellular space, the ECV can act as a fibrosis index. ECV is correlated with the amount of fibrosis measured by histology. Left ventricular overloads induced by regurgitant VHD result in cardiomyocyte hypertrophy and diffuse fibrosis. Other methods can be used to estimate the degree of myocardial fibrosis such as the serum level of galectine-3 or ST2. Moreover, although the pathophysiological mechanisms leading to the occurrence of myocardial fibrosis differ in patients with various cardiac diseases, the cellular effectors of fibrotic remodelling are common and involve similar signalling pathways. At the cellular level, key progression of ventricular hypertrophy is associated with increased cardiomyocytes apoptosis and fibrosis, suggesting that these two processes are responsible for the transition.

To our knowledge, no study has analysed the impact of the rate of myocardial diffuse fibrosis, non-invasively estimated by ECV, in the risk of LV dysfunction during MR and AR, especially after surgery. The measurement of ECV could become an important tool for risk stratification in left-sided regurgitant VHD. Thus, it would provide an early marker of LV myocardial involvement before the occurrence of global remodeling, might help physicians in surgical decision, and would improve prognosis. This is an innovative original project because it uses modern imaging modalities to answer to a crucial question. The clinical implications would be important because this work would modify the international surgical indications of MR and AR in order to finally improve the prognosis of patients with this frequent heart disease. Moreover, investigators will analyze the genetic factors that can influence the myocardial reaction resulting from these regurgitations, which will improve the quality of this work and offer new future perspectives.

Investigators hypothesize that the ECV measurement could be used as an early predictor of LV dysfunction in the left-sided valve regurgitations.

03

Conditions studied

  • Valve Heart Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All consecutive patients referred for organic MR and/or AR at least moderate to severe according to the ESC guidelines criteria⁴ will be eligible. The moderate to severe criteria will defined by echocardiography as followed:
  • MR: an effective regurgitant orifice area (EOA) >30mm2 and/or a regurgitant volume (RV) >45mL
  • AR: an EOA >20mm2 and/or a RV >45mL

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Pregnancy
  • Impossibility to maintain a decubitus position
  • Arrhythmia that do not allow an synchronization during MRI
  • Hemodynamic instability
  • Indication of urgent surgery
  • Known coronary artery disease
  • Severe arterial hypertension
  • Cardiomyopathy
  • Claustrophobia
  • Gadolinium intolerance
  • Implantable medical devices that do allow to perform MRI
  • Severe renal insufficiency with clearance \<35 mL/min
  • Vulnerable patients
  • Acute infective endocarditis
  • Aortic dissection
  • Moderate or severe mitral stenosis (mitral area \<1.5cm2/m2)
  • Moderate or severe aortic stenosis (aortic area \<0.8cm2/m2, or Vmax>3m/s, or mean gradient>30mmHg)
  • Previous cardiac surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    organic left-sided regurgitant valve

    Device: Cardiac MRI · Biological: blood samples · Procedure: myocardial biopsy · Genetic: blood samples

Interventions

  • DeviceCardiac MRI
  • Biologicalblood samples

    Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured

  • Proceduremyocardial biopsy
  • Geneticblood samples

    extract DNA to look for genomic mutations associated with the disease.

06

What researchers measure

Primary outcomes

  1. the rate of diffuse myocardial fibrosis

    Time frame: 6 months

Secondary outcomes

  1. Correlations between ECV and the global longitudinal strain and the serum level of Galectin-3 and ST2

    Time frame: 42 months

  2. Correlations between ECV changes and genetic factors

    Time frame: 42 months

  3. correlations between ECV and the severity of the regurgitation

    Time frame: 42 months

  4. correlation between ECV and the myocardial deformation quantified by speckle tracking echocardiography (2D Strain)

    Time frame: 42 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2016 (actual). Primary completion is estimated for Nov 2026, 126 months after the start.

Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 126 months is above that.

Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2016
First posted
Apr 21, 2016
StartActual
May 2016
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02747485
Responsible party
Sponsor
First posted
Apr 21, 2016
Start date
May 2016
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
May 19, 2026

Study contacts

Catherine GEINDRE
study director · Assistance Publique Hopitaux De Marseille

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion